Renalytix Plc (AIM:RENX)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 32.91M -9.8% |
| Revenue (ttm) | 2.45M +40.3% |
| Net Income | -14.79M |
| EPS | -0.04 |
| Shares Out | 603.83M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 368,917 |
| Open | 5.50 |
| Previous Close | 5.45 |
| Day's Range | 5.30 - 5.60 |
| 52-Week Range | 1.60 - 10.00 |
| Beta | 1.61 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Dec 24, 2026 |
About Renalytix
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. The company’s products are used in kidney disease diagnosis and prognosis, cl... [Read more]
Financial Performance
In fiscal year 2025, Renalytix's revenue was $3.00 million, an increase of 30.43% compared to the previous year's $2.30 million. Losses were -$20.40 million, -55.16% less than in 2024.
Financial numbers in USD Financial StatementsNews
Renalytix Transcript: Investor update
A national distribution deal with Quest Diagnostics will provide access to half of U.S. physicians and hospitals, enabling a major scale-up for KidneyIntelX, an FDA-approved prognostic test for chronic kidney disease. Financials are strengthened, costs are controlled, and the company targets 25,000 tests in 2027, with global expansion and pharma collaborations underway.
Renalytix Slides: Investor update
Renalytix has posted slides in relation to its latest quarterly earnings report, which was published on September 29, 2026.
KidneyIntelX® Delivers Unprecedented Two-Year Real-World Outcomes in Diabetic Kidney Disease: No Comparable Risk Assessment Tool Exists
Landmark study of 2,470 patients across two U.S. health systems demonstrates sustained risk-stratified improvements in kidney function, increases in guideline-directed therapy uptake, and - for the fi...
Renalytix™ and Carna Health Partner to Solve Kidney Disease Crisis: Bridging the Existing Gap Between Population Screening and Precision Intervention
The novel care model will integrate FDA-approved kidneyintelX.dkd™ and Carna Health's digital health platform to identify at-risk patients, halt disease progression, and slash healthcare costs, signi...
Renalytix Quarterly report: H1 2026
Renalytix has published its H1 2026 quarterly earnings report on March 26, 2026.
Renalytix Earnings release: H1 2026
Renalytix released its H1 2026 earnings on February 11, 2026, summarizing the period's financial results.
Pivotal kidneyintelX.dkd Data Published in Diabetes Care, Considered the Leading Clinical Journal Worldwide in Diabetes
New results and three presentations at ASN Kidney Week underscore kidneyintelX.dkd as a precision-medicine standard for CKD NEW YORK , Nov. 18, 2025 /PRNewswire/ -- Renalytix plc (LSE: RENX) (OTCQB: R...
Renalytix Annual report: Q4 2025
Renalytix has published its Q4 2025 annual report on November 4, 2025.
Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease
Definitive agreement to accelerate adoption of Renalytix's FDA-approved, Medicare reimbursed kidneyintelX.dkd test to slow kidney disease progression and improve patient outcomes NEW YORK , Sept. 15, ...
MVP Health Care and Renalytix Partner to Bring Life-Changing Kidney Disease Testing to Local Communities
New partnership expands access to prognostic testing for people with diabetic kidney disease, helping improve lives and reduce health disparities. NEW YORK , July 21, 2025 /PRNewswire/ -- Renalytix Pl...
Renalytix Earnings release: Trading Update
Renalytix released its earnings on April 10, 2025, summarizing the period's financial results.
Renalytix Earnings Call Transcript: Q2 2025
Revenue is on track for $3.2M in FY2025 with 20% quarterly growth, driven by Medicare coverage and direct-to-doctor sales. Operational improvements have reduced costs and turnaround times, while strategic pharma collaborations and a strong US focus support future expansion.
Renalytix Quarterly report: Q2 2025
Renalytix has published its Q2 2025 quarterly earnings report on March 18, 2025.
Renalytix Slides: Q2 2025
Renalytix has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on March 18, 2025.
Renalytix Earnings release: Trading Update
Renalytix released its earnings on January 27, 2025, summarizing the period's financial results.
Renalytix Proxy statement: Proxy Filing
Renalytix filed a proxy statement on November 25, 2024, providing details for shareholder voting and corporate governance matters.
Renalytix Annual report: Q4 2024
Renalytix has published its Q4 2024 annual report on November 25, 2024.
Renalytix Quarterly report: Q4 2024
Renalytix has published its Q4 2024 quarterly earnings report on November 25, 2024.
Renalytix Annual report: Q4 2024
Renalytix has published its Q4 2024 annual report on November 25, 2024.
Renalytix plc Reports Financial Results for First Quarter of Fiscal Year 2025
LONDON and NEW YORK , Nov. 20, 2024 /PRNewswire/ -- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management...
Renalytix Proxy statement: Proxy Filing
Renalytix filed a proxy statement on November 12, 2024, providing details for shareholder voting and corporate governance matters.
Renalytix Proxy statement: Proxy Filing
Renalytix filed a proxy statement on October 11, 2024, providing details for shareholder voting and corporate governance matters.
Renalytix commences trading on OTCQB in U.S.
Renalytix announces that as previously disclosed regarding its intention to move listing of its American Depository Shares from Nasdaq to the OTC Markets Group Inc., that effective with the market…
Renalytix Proxy statement: Proxy Filing
Renalytix filed a proxy statement on October 1, 2024, providing details for shareholder voting and corporate governance matters.
Renalytix announces collaboration with Steno Diabetes Center
Renalytix announces a collaboration with the Steno Diabetes Center, Copenhagen, to advance translation of precision medicine solutions for patients with Diabetes and Chronic Kidney Disease, DKD. The i...